Possibilities of pathogenetic therapy of patients with inflammatory diseases of the paranasal sinuses

Cover Page

Cite item

Full Text

Abstract

Rhinosinusitis is one of the most common pathological process in the human population. Principles of treatment of patients with rhinosinusitis are reflected in the Russian and international clinical guidelines, which are regulary revisied. Inflammation during rhinosinusitis causes the block of natural anastomoses of paranasal sinuses, violation of aeration, inactivation of mucociliary clearance and stagnation of fluid in the lumen of the sinuses. In uncomplicated rhinosinusitis the main goal of therapy is the elimination of the inflammatory process and restoring of the sinuses normal functioning. The most effective drugs are intranasal corticosteroids that are recommended as monotherapy in post-viral rhinosinusitis, or in combination with systemic antibiotic therapy in patients with bacterial rhinosinusitis. For the treatment of rhinosinusitis only mometasone is registered in our country. There are several mometasone drugs from different manufacturers, including mometasone nasal spray of the pharmaceutical company TEVA, Dezrinit. Research results confirm that Dezrinit meets the same quality standards as the original drug.

About the authors

Valerii M. Svistushkin

Sechenov First Moscow State Medical University (Sechenov University)

Email: *svvm3@yandex.ru
D. Sci. (Med.), Prof. Moscow, Russia

Galina N. Nikiforova

Sechenov First Moscow State Medical University (Sechenov University)

D. Sci. (Med.), Prof. Moscow, Russia

Elena A. Shevchik

Sechenov First Moscow State Medical University (Sechenov University)

Cand. Sci. (Med.) Moscow, Russia

Anna V. Zolotova

Sechenov First Moscow State Medical University (Sechenov University)

Cand. Sci. (Med.) Moscow, Russia

Marica G. Dedova

Sechenov First Moscow State Medical University (Sechenov University)

Аssistant Moscow, Russia

Olga Iu. Karpova

Sechenov First Moscow State Medical University (Sechenov University)

D. Sci. (Med.), Prof. Moscow, Russia

References

  1. Клинические рекомендации. Острый синусит. http://glav-otolar.ru/klinicheskie-rekomendaczii/ @@Klinicheskie rekomendatsii. Ostryi sinusit. http://glav-otolar.ru/klinicheskie-rekomendaczii/ (in Russian).
  2. Fokkens W.J, Lund V.J, Mullol J et al. European Position Paper on Rhinosinusitis and Nasal Polyps 2012. Rhinol Suppl 2012; 23: 1-298. https://doi.org/10.4193/Rhino50E2
  3. Крюков А.И. и др. Лечебно-диагностическая тактика при остром бактериальном синусите. Методические рекомендации Департамента здравоохранения Москвы. М., 2002. @@Kryukov A.I. et al. Therapeutic and diagnostic tactics in acute bacterial sinusitis. Methodological recommendations of the Moscow Department of Health. Moscow, 2002 (in Russian).]
  4. Лопатин А.С., Свистушкин В.М. Острый риносинусит: этиология, патогенез, диагностика и принципы лечения. Клинические рекомендации. М.: Российское общество ринологов, 2009. @@Lopatin A.S., Svistushkin V.M. Acute rhinosinusitis: etiology, pathogenesis, diagnosis and treatment principles. Clinical recommendations. Moscow: Russian Society of Rhinologists, 2009 (in Russian).]
  5. Jaakkola M.S, Jaakkola J.J. Office equipmentand supplies: a modern occupational health concern? Am J Epidemiol 1999. https://doi.org/150(11):1223-8.10.1093/oxfordjournals.aje.a009949
  6. Zuskin E, Mustajbegovic J, Schachter E.N et al. Respiratory findings in pharmaceutical workers. Am J Ind Med 2004; 46 (5): 472-9. https://doi.org/10.1002/ajim.20085
  7. Рязанцев С.В. Принципы этиопатогенетической терапии острых синуситов (методические рекомендации). СПб., 2013.@@Ryazantsev S.V. Principles of etiopathogenetic therapy of acute sinusitis (Guidelines). Saint Petersburg, 2013 (in Russian).
  8. Учайкин В.Ф., Нисевич Н.И., Шамшева О.В. Инфекционные болезни у детей. М.: ГЭОТАР-Медиа, 2006. @@Uchaikin V.F., Nisevich N.I., Shamsheva O.V. Infectious diseases in children. Moscow: GEOTAR-Media, 2006 (in Russian)
  9. Heikkinen T, Jarvinen A. The common cold. Lancet 2003 Jan 4. https://doi.org/361(9351):51-9.10.1016/S0140-6736(03)12162-9
  10. Страчунский Л.С., Тарасов А.А., Крюков А.И. и др. Возбудители острого бактериального риносинусита. Результаты многоцентрового микробиологического исследования SSSR. Клин. микробиол. антимикроб. химиотер. 2005; 7 (4): 337-49. @@Strachunskii L.S., Tarasov A.A., Kriukov A.I. et al. Vozbuditeli ostrogo bakterial'nogo rinosinusita. Rezul'taty mnogotsentrovogo mikrobiologicheskogo issledovaniia SSSR. Klin. mikrobiol. antimikrob. khimioter. 2005; 7 (4): 337-49 (in Russian)
  11. Anand V.K. Epidemiology and economic impact of rhinosinusitis. Ann Otol Rhinol Laryngol Suppl 2004; 193: 3-5.
  12. Payne S.C, Benninger M.S. Staphylococcus aureus is a major pathogen in acute bacterial rhinosinusitis: a metaanalysis. Clin Infect Dis 2007; 45 (10): e121-7. https://doi.org/10.1086/522763
  13. Колосов А.В., Гучев И.А., Кречикова О.И. Острый бактериальный риносинусит у военнослужащих: этиология, чувствительность к антибиотикам и эффективность антимикробной терапии. Клин. микробиол. антимикроб. химиотер. 2009; 11 (1): 14-21. @@Kolosov A.V., Guchev I.A., Krechikova O.I. Ostryi bakterial'nyi rinosinusit u voennosluzhashchikh: etiologiia, chuvstvitel'nost' k antibiotikam i effektivnost' antimikrobnoi terapii. Klin. mikrobiol. antimikrob. khimioter. 2009; 11 (1): 14-21 (in Russian)
  14. Ryan D. Management of acute rhinosinusitis in primary care: changing paradigms and the emerging role of intranasal corticosteroids. Prim Care Respir J 2008; 17 (3): 148-55. https://doi.org/10.3132/pcrj.2008.00050
  15. Schleimer R.P, Kato A, Peters A et al. Epithelium, inflammation, and immunity in the upper airways of humans: studies in chronic rhinosinusitis. Proc Am Thorac Soc 2009; 6 (3): 288-94. https://doi.org/10.1513/pats.200808-088RM
  16. Berkowitz R.B, Bernstein D.I, LaForce C et al. 10.1513/pats.200808-088RM Onset of action of mometasone furoate aqueous nasal spray (Nasonex) in seasonal allergic rhinitis. Allergy 1999; 54: 64-9.
  17. Fokkens W.J, Jogi R, Reinartz S et al. Once daily fluticasone furoate nasal spray is effective in seasonal allergic rhinitis caused by grass pollen. Allergy 2007; 62: 1078-84. https://doi.org/10.1111/j.1398-9995.2007.01522.x
  18. Ненашева Н.М. Фликсоназе: новые возможности в терапии аллергического ринита. Практический врач. 1996; 5-6 (3); Вып. 2: 19-20.@@Nenasheva N.M. Fliksonaze: novye vozmozhnosti v terapii allergicheskogo rinita. Prakticheskii vrach. 1996; 5-6 (3); Vyp. 2: 19-20 (in Russian).
  19. Brannan M.D, Seiberling V, Cutler D.L et al. Lack of systemic activity with intranasal mometasone furoate. Ann Allergy Asthma Immunol 1997; 97: 198.
  20. Sastre J, Mosges R. Local and systemic safety of intranasal corticosteroids. J Investig Allergol Clin Immunol 2012; 22 (1): 1-12. https://doi.org/10.1016/S0091-6749(99)70311-8
  21. Лещенко И.В. Место и значение способа доставки ингаляционных глюкокортикостероидов в терапии больных бронхиальной астмой. Consilium Medicum. 2008; 10 (3): 2-9. @@Leshhenko I.V. Place and significance of the method of delivery of inhaled glucocorticosteroids in the treatment of patients with bronchial asthma. Consilium Medicum. 2008; 10 (3): 2-9 (in Russian).
  22. Minshall E, Ghaffar O, Cameron L et al. Assessment by nasal biopsy of long-term use of mometasone furoate aqueous spray (Nasonex) in the treatment of perennial rhinitis. Otolaryngol Head Neck Surg 1998; 118: 648-54. https://doi.org/10.1177/019459989811800514
  23. Wolthers O.D. Relevance of pharmacokinetics and bioavailability of intranasal corticosteroids in allergic rhinitis. Recent Pat Inflamm Allergy Drug Discov 2010; 4 (2): 118-23.
  24. Sastre J, Mosges R. Local and systemic safety of intranasal corticosteroids. J Investig Allergol Clin Immunol 2012; 22 (1): 1-12.
  25. Инструкция по медицинскому применению лекарственного препарата Дезринит. https://teva.ru/uploads/catalog/files/5c015fd156464.pdf/ @@Instruktsiia po meditsinskomu primeneniiu lekarstvennogo preparata Dezrinit. https://teva.ru/ uploads/catalog/files/5c015fd156464.pdf/ (in Russian).
  26. Ильина Н.И., Федоскова Т.Г., Астафьева Н.Г. и др. Терапевтическая сопоставимость препаратов Дезринит и Назонекс в решении вопросов контроля симптомов аллергического ринита. Результаты многоцентрового, открытого, рандомизированного, сравнительного исследования в параллельных группах. Рос. аллергологический журн. 2016; 3: 65-74. @@Il'ina N.I., Fedoskova T.G., Astaf'eva N.G. et al. Terapevticheskaia sopostavimost' preparatov Dezrinit i Nazoneks v reshenii voprosov kontrolia simptomov allergicheskogo rinita. Rezul'taty mnogotsentrovogo, otkrytogo, randomizirovannogo, sravnitel'nogo issledovaniia v parallel'nykh gruppakh. Ros. allergologicheskii zhurn. 2016; 3: 65-74 (in Russian)
  27. Шахова Е.Г. Место топических глюкокортикостероидов в лечении риносинусита. Вестн. оториноларингологии. 2017; 82 (2): 70-3. @@Shakhova E.G. Mesto topicheskikh gliukokortikosteroidov v lechenii rinosinusita. Vestn. otorinolaringologii. 2017; 82 (2): 70-3 (in Russian)

Copyright (c) 2019 Consilium Medicum

Creative Commons License
This work is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License.

This website uses cookies

You consent to our cookies if you continue to use our website.

About Cookies